drugset / Trial / NCT01215357

Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble

NCT01215357

Phase 2 Completed 34 enrolled Emalex Biosciences Inc. Psyadon Pharma · collab
Non-randomizedSequentialSingle-blindTreatment

Summary

This study is designed to test the hypothesis that ecopipam is able to reduce urges to gamble in patients diagnosed with Pathological Gambling.

Timeline

Start
2010-10
Primary completion
2012-05
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Ecopipam Small molecule 50 mg Oral

Indications